Patents Assigned to SEAGEN INC.
  • Process for the preparation of drug linker compounds
    Patent number: 11612666
    Abstract: This disclosure generally relates to novel processes for the preparation of drug linker compounds and compositions comprising such drug linker compounds. The presently disclosed methods for synthesizing Fmoc-Val-Cit-PABOH and related compounds have also been found to minimize formation of diastereomeric impurities.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: March 28, 2023
    Assignee: Seagen Inc.
    Inventors: Sophie Blanchard, James Coats
  • Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
    Patent number: 11607460
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 21, 2023
    Assignee: SEAGEN INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Anti-TIGIT Antibodies
    Publication number: 20230050440
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 16, 2023
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS
    Publication number: 20230034390
    Abstract: The present invention provides an analytical method for separating and optionally quantifying two or more buffers or excipients in a sample in a single assay.
    Type: Application
    Filed: December 15, 2020
    Publication date: February 2, 2023
    Applicants: Seagen Inc., Seagen Inc.
    Inventors: Jing Liu, Ethan Tyler Brickman, Luke David Munier Cody
  • Compositions and Methods for Targeting Cancer Stem Cells
    Publication number: 20230029085
    Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
    Type: Application
    Filed: March 16, 2022
    Publication date: January 26, 2023
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20230025600
    Abstract: Provided herein are methods for the treatment of cancers with antibody drug conjugates (ADC) that bind to 191P4D12 proteins. Also provided herein are methods for the treatment of urothelial cancer using an antibody drug conjugate (ADC) that binds 191P4D12. Additionally provided herein are methods for the treatment of solid tumors using an antibody drug conjugate (ADC) that binds 191P4DI2.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 26, 2023
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Elaina Marie GARTNER, Amal MELHEM-BERTRANDT, Leonard Michael Jude REYNO, Jonathan Gregor DRACHMAN
  • Compositions and Methods for Targeting Cancer Stem Cells
    Publication number: 20230022411
    Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
    Type: Application
    Filed: March 16, 2022
    Publication date: January 26, 2023
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 11559558
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: January 24, 2023
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 11559582
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: January 24, 2023
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20230001005
    Abstract: Provided herein are methods for the treatment of cancers with antibody drug conjugates (ADC) that bind to 191P4D12 proteins.
    Type: Application
    Filed: August 10, 2020
    Publication date: January 5, 2023
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventor: Oyewale O. ABIDOYE
  • Glycan-Interacting Compounds and Methods of Use
    Publication number: 20230001007
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Application
    Filed: January 4, 2022
    Publication date: January 5, 2023
    Applicant: Seagen Inc.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Multi-drug antibody drug conjugates
    Patent number: 11541128
    Abstract: The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units, that are constructed in a site-specific matter via ‘orthogonal’ deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: January 3, 2023
    Assignee: Seagen Inc.
    Inventor: Matthew R. Levengood
  • Hydrophilic antibody-drug conjugates
    Patent number: 11510959
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: November 29, 2022
    Assignee: Seagen Inc.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Methods of Purifying Masked Antibodies
    Publication number: 20220306727
    Abstract: The present invention relates to the field of antibody formulations. In particular, the present invention relates to specific methods of preparing masked antibodies with reduced aggregation. In some embodiments, the masked antibodies comprise anti-CD47 antibodies.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 29, 2022
    Applicant: Seagen Inc.
    Inventors: Elise Cunningham, Susan Lee, Danielle Leiske, Catherine Eakin, Kevin Beam, Lori Westendorf, Michael Feldhaus, Samuel Pearce Alcoba
  • Glycan-Interacting Compounds and Methods of Use
    Publication number: 20220259323
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
    Type: Application
    Filed: December 1, 2021
    Publication date: August 18, 2022
    Applicant: Seagen Inc.
    Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
  • Anti-TIGIT antibodies
    Patent number: 11401339
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • Glycan-interacting compounds and methods of use
    Patent number: 11401330
    Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • Masked Antibody Formulations
    Publication number: 20220233709
    Abstract: Formulations comprising masked antibodies are provided. In some embodiments, there is reduced aggregation of the masked antibodies in the formulations. In various embodiments, the formulations are pharmaceutical formulations suitable for use in therapeutic treatment.
    Type: Application
    Filed: June 4, 2020
    Publication date: July 28, 2022
    Applicant: Seagen Inc.
    Inventors: Danielle Leiske, Elise Cunningham, Shan Jiang, Lori Westendorf, Michael Feldhaus, Eoin Francis James Cosgrave, Catherine Marie Eakin
  • Process for the preparation of tubulysins and intermediates thereof
    Patent number: 11389543
    Abstract: Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 19, 2022
    Assignee: Seagen Inc.
    Inventors: Kun-Liang Wu, Qingwu Jin, Wendel Doubleday
  • Glycan-interacting compounds and methods of use
    Patent number: RE49435
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: February 28, 2023
    Assignee: Seagen Inc.
    Inventors: Julie DeSander, Jeffrey Behrens